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Abstract Increased levels of reactive oxygen species
(ROS) by hyperglycemia can induce apoptosis of renal
cells and diabetic nephropathy. The redox balance in the
renal cell seems, therefore, of the utmost importance. ROS-
mediated apoptosis may be further aggravated by an
inadequate cytoprotective response against ROS. When
there are insufﬁcient cytoprotective and ROS scavenging
molecules, ROS lead to considerable cellular damage and
to a point of no return in apoptosis. Induction of cytopro-
tective proteins may prevent or attenuate apoptosis, renal
cell injury, and ﬁnally diabetic nephropathy. Here, we
discuss some mechanisms of apoptosis and several strate-
gies that have been probed to ameliorate, or to prevent
apoptosis in the diabetic kidney.
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Abbreviations
AGE Advanced glycation end products
Apaf-1 Apoptotic protease activating factor-1
Bcl2 B-cell lymphoma 2
CO Carbon monoxide
DISC Death-inducing signaling complex
DNA Deoxyribonucleic acid
ECM Extracellular matrix
EPCR Endothelial PC-receptor
FADD Fas-associated death domain
GBM Glomerular basement membrane
GSH Glutathione
HO Heme oxygenase
MAC Mitochondrial apoptosis-induced channel
MAPK Mitogen-activated protein kinases
MOMP Mitochondrial outer membrane
permeabilization
NADPH Nicotinamide adenine dinucleotide phosphate
NO Nitric oxide
PAR-2 Protease-activated receptor-1
PARP Poly (ADP-ribose) polymerase
PC Protein C
PTPC Permeability transition pore complex
ROS Reactive oxygen species
RNS Reactive nitrogen species
Smac Second mitochondria-derived activator of
caspases
SOD Superoxide dismutase
STZ Streptozotocin
TNFa Tumor necrosis factor-a
TRADD TNF-receptor-associated death domain
TRAIL TNF-related apoptosis-inducing ligand
VEGF Vascular endothelial growth factor
Wnt Wingless-type MMTV integration site family
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Diabetes mellitus forms an enormous and still increasing
health burden worldwide [1]. Mortality and morbidity are
caused in particular by the occurrence of complications [2].
One of the microvascular complications is diabetic
nephropathy in both T1DM and T2DM, which is the
leading cause of adult renal failure at the moment [3]. A
key role in the pathogenesis of diabetic nephropathy has
been attributed to hyperglycemia as it leads to the forma-
tion of advanced glycation end products (AGEs) and the
mitochondrial production of reactive oxygen species
(ROS), and, subsequently, to cell death and kidney dys-
function [4]. In this review, we will focus on the patho-
genic role of oxidative stress and apoptosis in diabetic
nephropathy. Potential strategies to prevent or treat the
renal damage inﬂicted by ROS-induced apoptosis are
discussed.
Diabetic nephropathy
Diabetic nephropathy can be characterized by both glo-
merular and tubulointerstitial injury, each, however, to a
hugely variable extent [5]. An important histological hall-
mark of diabetic nephropathy is proliferation of mesangial
cells, and, as a result, the expansion of extracellular matrix
(ECM) in the mesangium [6]. Thickening of the glomerular
basement membrane (GBM) is another feature of diabetic
nephropathy [7]. One of the clinical manifestations and
main predictor of diabetic nephropathy is emerging mi-
croalbuminuria in the early phase of the disease that further
develops to massive macroalbuminuria during overt dia-
betic nephropathy and end stage renal disease. Damage to
the capillary ﬁlter, existing of podocytes, GBM and glo-
merular endothelium, may be responsible for the devel-
opment of albuminuria. We have recently shown that
heparanase-mediated loss of heparan sulfate in the GBM is
a possible key mediator in the development of proteinuria
and overt diabetic nephropathy. However, we could also
observe changes in tubular heparan sulfate [8–12]. Notably,
an aberrant expression of heparanase and heparan sulfate in
certain cancer cells has been implicated to play a role in
apoptosis [13, 14]. However, the possible role of renal
heparanase expression in apoptosis during the development
of diabetic nephropathy remains to be addressed. Histori-
cally, mesangial cells have been attributed a central role in
glomerular-associated diabetic nephropathy. However, also
other glomerular cell types, like endothelial cells, and
podocytes have been implicated in the genesis of diabetic
nephropathy, while inﬂammatory cells such as macro-
phages can further exacerbate the oxidative stress and
inﬂammatory processes leading to apoptosis.
Alternatively, renal deterioration may also be related to
chronic hypoxia, that can for example occur following
vasoconstriction by decreased levels of nitric oxide (NO)
or increased levels of angiotensin II [15]. The occurrence
of interstitial ﬁbrosis may additionally deteriorate the dif-
fusion of oxygen to the renal cells. During hypoxia ROS
formation can occur via increased electron ﬂow at complex
III of the mitochondrial electron transport chain and via
NADPH oxidase [16, 17]. Experimental research has
shown that hyperglycemia interferes with the beneﬁcial
VEGF response to hypoxia in proximal tubular cells [18].
As a result, these and numerous other factors may cause
hypoxia, the formation of ROS, cellular injury and ﬁnally
apoptosis of renal cells. In summary, both the glomerular
and the tubular compartment may be involved in the ini-
tiation of diabetic nephropathy.
Redox balance in the kidney
Within renal cells a balance between pro- and anti-oxidants
is kept under physiological conditions. Although ROS have
important functions in normal cellular signaling and regu-
lation, in excess, they may result in oxidative damage to
proteins,lipidsandDNA,ultimatelyleadingtoapoptosisand
renalinjury[19].ROScanactivateseveralpro-inﬂammatory
transcriptionfactors,resultingintheproductionofcytokines
and chemokines and vascular adhesion molecules, and,
subsequently, the inﬂux of inﬂammatory cells into the kid-
ney. This formation of renal inﬂammation initiated by ROS
further prolongs and exacerbates ROS-mediated cell injury,
apoptosisandkidneydysfunction.Tokeeptheredoxbalance
under control a complex network of pro- and anti-oxidant
enzymes exists. However, it can be envisioned that in case
the cytoprotective anti-oxidant factors, as exempliﬁed in
Fig. 1, get overwhelmed as may occur following hypergly-
cemia,thebalancegetsskewedtowardsoxidativestress,and
may lead to apoptosis and kidney injury.
Mitochondria-derived ROS constitute the main source
of intracellular ROS that are responsible for apoptosis and
diabetic nephropathy [20, 21]. As described above, both the
glomeruli and the tubulointerstitial compartments can be
subjected to the hyperglycemia-induced increase in mito-
chondrial ROS production. During periods of hyperglyce-
mia, renal cells fail to attenuate the entrance of glucose into
the cell, resulting in such increased substrate levels for the
mitochondrial electron transport chain that this leads to an
overﬂow of the respiratory chain. Normally, a small
amount of ROS are formed as a result of electron carriers
reacting directly with oxygen, but during this overﬂow
backed up electrons result in even more reactive electron
carriers and thus enhanced production of ROS. It has been
demonstrated that high glucose levels result in increased
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123levels of ROS, AGEs and sorbitol, and higher activity of
protein kinase C that have been demonstrated to contribute
to cellular injury and apoptosis [22].
Other strong contributors to ROS formation in the dia-
betic kidney are the superoxide producing enzyme NADPH
oxidase (NOX), and xanthine oxidase, which catalyzes
oxidation of hypoxanthine (the occurrence of different
NOX isoforms in different cells of the diabetic kidney is
reviewed in [4]). Nitric oxide synthase produces the free
radical nitric oxide, which, under normal conditions acts
protective, but under oxidative circumstances, can be
converted into other reactive nitrogen species (RNS),
including peroxynitrite [23].
On the other hand, there are intrinsic renal cytoprotec-
tive anti-oxidant factors and protein responses that keep the
ROS and RNS in balance. The cytoprotective anti-oxidant
proteins include for example superoxide dismutases (SOD)
that convert superoxide to hydrogen peroxide, which, in
turn, is rendered inactive by catalase and glutathione per-
oxidase. The heme oxygenase (HO) system is another
crucial anti-oxidant system in the kidney [24, 25]. HO
degrades the pro-oxidant heme into iron, carbon monoxide
and biliverdin [23]. Biliverdin is than directly converted
into the strong anti-oxidant bilirubin by biliverdin reduc-
tase. HO-derived iron can, like heme, catalyze the Fenton
reaction resulting in the production of reactive hydroxyl
groups, but is scavenged by co-induced ferritin [23]. The
strongly inducible HO-1 isoform has been shown to protect
against oxidative stress, inﬂammation and apoptosis in the
kidney [23, 26–28], and also the constitutively expressed
HO-2 isoform is getting recognized for its protection
against oxidative stress and inﬂammatory processes [29].
In addition to an increased formation of ROS, a decreased
anti-oxidant capacity results in skewing of the redox bal-
ance. It is likely that in diabetes patients a combination of
increased ROS formation and diminished anti-oxidant
defense results in apoptosis of renal cells. This is exem-
pliﬁed by the ﬁndings of Quan et al., who demonstrated
that hyperglycemia decreases HO-activity in the aortic
endothelium and increases the production of ROS [30],
suggesting that patients with hyperglycemia are deprived
from the protective effects of the HO-effector molecules
CO, bilirubin and ferritin. Moreover, hyperglycemia was
shown to decrease the protective effect of the HO-system
in the vascular system of animal models [30, 31], resulting
in an impaired defense against oxidative stress and
inﬂammation [30, 32]. In addition, it has been shown that
HO-1 and the cytoprotective heat shock protein 72
expression is decreased in skeletal muscles of patients with
type 2 diabetes (T2DM) [33]. In contrast, Hayashi dem-
onstrated that during streptozotocin (STZ)-induced diabe-
tes in rats, which is an established model for mainly
T1DM, HO-1 levels were up-regulated in glomeruli,
whereas the expression of other cytoprotective enzymes
such as catalase, GSH peroxidase and Cu-, Zn- superoxide
dismutase were unchanged compared to control rats [34,
35]. Several studies have shown a protective role of HO-1
against oxidants in the kidney, as reviewed in [36, 37]. In
summary, when hyperglycemia leads to the sudden pro-
duction of ROS, and the anti-oxidant capacity is not suf-
ﬁcient, induction of apoptosis leads to renal injury and
diabetic nephropathy.
Fig. 1 Excess ROS leads to
apoptosis and diabetic
nephropathy. Model
demonstrating the different
causes of ROS formation that
result in the induction of
inﬂammation by pro-
inﬂammatory genes, leukocyte
inﬁltration, and aggravation of
ROS formation. Ultimately, this
may lead to apoptosis and
kidney dysfunction. We
postulate that in humans
induction of cytoprotective
proteins, such as HO-1, SOD or
catalase, will restore this ROS-
mediated skewing of the redox
balance by generating products
that protect against oxidative
stress, and/or inﬂammation and
apoptosis, or a combination
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123Mechanisms of apoptosis
Theapoptoticprocessisregulatedbycertainproteins,theso-
called cysteine-dependent speciﬁc aspartate proteases or
caspases. Caspases have a role in the induction of apoptosis
as well as in the execution phase of apoptosis, and play a
central role in diabetic nephropathy. Caspase-dependent
apoptosis can be induced by either the extrinsic or the
intrinsic pathway.
The extrinsic pathway involves a death-inducing ligand
such as for example Fas ligand (FasL) or TNFa interacting
with their corresponding death receptor on the plasma
membrane, for this example Fas receptor and TNF receptor,
respectively. After binding of these ligands to the death
receptors Fas-associated death domain (FADD) or TNF-
receptor-associated death domain (TRADD), caspase-8 is
recruited and activated to form a death-inducing signaling
complex (DISC). DISC can propagate the death signal
directly by activating the effector caspases-3, -6 and -7 [38,
39], or indirectly via cleavage of Bid, which upon translo-
cation to the mitochondria leads to mitochondrial outer
membrane permeabilization (MOMP) and subsequent
releaseofpro-apoptoticproteins,such ascytochrome c [40].
Cytochrome c is part of the caspase-dependent intrinsic
pathway discussed below and can interact with apoptotic
protease activating factor-1 (Apaf-1) and procaspase 9 to
form an apoptosome. This complex is able to activate cas-
pase 9, which in turn activates the effector caspases 3, 6 and
7, leading to apoptosis [41].
The secondapoptotic pathway is the intrinsic pathway, in
which the mitochondrion is the central regulator [42]. The
point-of-no-returnfortheintrinsicpathwayisMOMP,which
is controlled by the family of Bcl-2 proteins [43]. Bcl-2
proteins are either anti-apoptotic (Bcl-2, Bcl-XL, Bcl-w) or
pro-apoptotic(Bax,Bak,Bad,Bim)andthebalancebetween
these two groups ultimately determines cell survival or cell
death. Especially the pro-apoptotic family member Bax
seems important since it can oligomerize or form complexes
withotherproteinstoformchannelssuchasthepermeability
transition pore complex (PTPC) and mitochondrial apopto-
sis-induced channel (MAC) in the mitochondrial outer
membrane, which can facilitate the release of pro-apoptotic
molecules such as cytochrome c [44–46].
Diabetes and apoptosis in the kidney
As outlined above, both acute and chronic hyperglycemia
leads to oxidative stress and this is the major trigger for
tubular and glomerular cells to go into apoptosis as deter-
minedinanimalmodelsandinvitrocellculturesystems[20,
22,47].HighglucoselevelscauseROS-dependentapoptosis
of mesangial cells via Bax-mediated mitochondrial
permeability and subsequent cytochrome c release [48]. In
murine and human renal mesangial cells high glucose levels
caused an increased Bax/Bcl-2 ratio, associated with cyto-
chromecreleasefrommitochondriaandsubsequentthepro-
apoptotic caspase-3 activation [49]. Enhanced levels of
glucose generated NADPH oxidase-mediated and mito-
chondrial-mediated ROS formation that activated pro-
apoptotic p38 MAPK and caspase-3 activation in podocytes
in vitro, whereas inhibition of NADPH oxidase-induced
ROS formation prevented podocyte apoptosis in vivo [50].
Inhibition of p38 MAPK inhibited the diabetes-mediated
decrease in the anti-apoptotic Bcl-2 expression and activa-
tion of caspase-3 in mesangial cells [51].
In renal tubular epithelial cells high glucose-mediated
oxidative stress induced an increased Bax protein expres-
sion, which was accompanied by a reduced Bcl-2 expres-
sion [52]. These data are in line with earlier ﬁndings that
during diabetes gene expression of pro-apoptotic Bax was
increased, whereas anti-apoptotic Bcl-2 and Bcl-XL
expression was down-regulated [53]. Different caspases, in
particular caspase-3 and -9 play a crucial role in high
glucose-induced apoptosis of proximal tubular epithelial
cells [54].
In a gene proﬁling study of the tubulointerstitium from
T1DM and T2DM nephropathy biopsy specimens it was
shown that two death receptors (osteoprotegerin and Fas),
and the death ligand TRAIL were strongly upregulated
[55]. Glomerular and proximal tubular expression of
TRAIL was conﬁrmed by immunohistochemistry and was
shown to be higher in diabetic kidneys than controls.
It was further found that protein C (PC) modulates
mitochondrial apoptosis in diabetic nephropathy [56]. In
glomerular endothelial cells, a complex of thrombomodulin
and thrombin activates PC, that subsequently activates the
protease-activated receptor-1 (PAR-1) in the proximity of
the endothelial PC-receptor (EPCR), resulting in cytopro-
tective signaling. Hyperglycemia interferes with thrombo-
modulin-dependent PC activation, resulting in less
protection and even promotion of release of apoptosis-
inducing factors like cytochrome c and Smac/Diablo
leading to apoptosis of endothelial cells and podocytes [19,
56].
In summary, data on renal apoptosis in diabetic
nephropathy are scarce and scattered, but both the intrinsic
and extrinsic apoptotic pathway seem to be involved.
Anti-oxidants and cytoprotective proteins in the
prevention of ROS-induced apoptosis of renal cells
and diabetic nephropathy
Several studies have targeted oxidative and nitrosative
stress, and thus apoptosis of renal cells caused by
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123hyperglycemia, through administration of anti-oxidants or
overexpression of cytoprotective proteins.
Anti-oxidant administration to animals has demon-
strated protective effects against the development of dia-
betic nephropathy. In addition to endogenous anti-oxidant
compounds like glutathione, thioredoxin, and biliverdin/
bilirubin also dietary anti-oxidants, such as vitamin C and
E and beta-carotene may restore the redox balance. The
number of apoptotic proximal tubular epithelial cells,
proteinuria, glomerular and tubulointerstitial sclerosis, and
renal malondialdehyde, as index of oxidative stress, were
signiﬁcantly decreased after anti-oxidant treatment with
vitamin C to T2DM rats when compared with untreated
T2DM rats [57]. Like vitamin C, vitamin E normalized
diabetes-induced renal dysfunction such as glomerular
volume and TGF-beta production in STZ-induced diabetic
rats [58]. High glucose-induced ROS formation and mes-
angial and proximal tubular epithelial cell apoptosis could
be inhibited in in vitro models, using the anti-oxidant
taurine [49, 52].
Unfortunately, translational studies to the administration
of solely anti-oxidants did not yet result in potent protection
against apoptosis in human diabetic nephropathy as
reviewed in [4]. Possibly induction of endogenous cytopro-
tective proteins (see Table 1) may be more efﬁciently
translated to the clinical situation than administered anti-
oxidants. Endogenous cytoprotective proteins may be tar-
getedtothekidneyorgeneratedinthekidney,and,therefore,
function more efﬁciently than exogenous added anti-oxi-
dants, since they act within the cell or cellular compartment
where ROS are actually generated. Recently, it was shown
that ROS production was reduced in a T1DM and T2DM
mouse models with transgenic overexpression of the anti-
oxidant enzyme catalase in proximal tubular cells [59, 60].
This resulted in reduced pro-apoptotic Bax and active
caspase-3 levels.Overexpression of catalase in the proximal
tubular cells protected diabetic mice from increased blood
pressure, albuminuria, glomerulosclerosis, interstitial ﬁbro-
sis and tubular apoptosis. These ﬁndings are in line with the
observationsthatcatalasedeﬁciencyinmicerenderskidneys
more prone to oxidative stress [61], while humans deﬁcient
in catalase are predisposed to cumulative oxidant damage
leading to T1DM and T2DM [62].
Pharmacological induction or gene transfer of HO-1 in
diabetic rats reduced ROS formation and caused an
increase in anti-oxidants biliverdin/bilirubin, which resul-
ted in an improvement of vascular and renal function [63].
Induction of HO-1 led to increased levels of the anti-
apoptotic phosphorylated AKT (pAkt) and BcL-XL.
Additionally, HO-2 deﬁciency enhanced STZ-induced
diabetic nephropathy, possibly via increased levels of
superoxide anions [64]. Pharmacological up-regulation of
HO-1 by heme or cobalt protoporphyrin in HO-2-deﬁcient
T1DM mice resulted in reduced superoxide anions and
improved diabetic kidney morphology and function [64].
Selective overexpression of the cytoprotective enzyme
HO-1 in the endothelial cell line HMEC-1 was shown to
prevent hyperglycemia-mediated O2
- formation and thus
blocked ROS-induced DNA damage and caspase activation
[25]. This study indicates that endothelial cell survival after
oxidative injury may be enhanced by increased HO-1
expression, thus blocking inﬂammation and apoptosis.
In isolated lymphocytes of patients affected by T2DM
complicated with nephropathy evidence was found of
systemic oxidative stress, and the observed induction of
HO-1 and thioredoxin reductase-1 was thought to reﬂect a
response in counteracting the intracellular pro-oxidant
status [65].
In mice overexpressing SOD, diabetes-induced renal
injury was also abrogated, most likely due to reduced
Table 1 Targeted cytoprotective genes and effects on renal cell apoptosis and nephropathy
Targeted genes in diabetic animal models Effects on diabetic renal cell apoptosis and nephropathy
Transgenic catalase mice Reduced albuminuria, glomerulosclerosis, interstitial ﬁbrosis and tubular apoptosis [59, 60]
Catalase-deﬁcient mice Kidneys are more prone to oxidative stress [61]
HO-1 gene transfer in mice or rats Reduced apoptosis and kidney injury [63]
HO-2-deﬁcient mice Enhanced STZ-induced diabetic nephropathy, which could be restored by HO-1 gene transfer
[64]
SOD transgenic mice Protection against diabetic nephropathy [68]
Thioredoxin-1 transgenic mice Diminished albuminuria and tubular apoptosis [67]
Peroxiredoxin-3 transgenic mice Protection against hyperglycemia and glucose intolerance and reduced ﬁbroblast apoptosis by
reducing mitochondrial H2O2 production [69]
Glutathione peroxidase-1-deﬁcient mice No effects on T1DM-induced kidney injury [70]
Mice with a reduction of thrombo-modulin-
dependent protein C activation
Aggravated glomerular apoptosis and diabetic nephropathy [19, 56]
Mice expressing a hyper-activatable protein C
mutation
Protein C activation prevents glomerular apoptosis and diabetic nephropathy [19, 56]
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increased anti-apoptotic glomerular Wnt5a/beta-catenin
signaling and abrogated diabetes-induced caspase-3
cleavage, DNA damage and subsequent mesangial apop-
tosis[68]. Overexpression of manganese (Mn)SOD that
exclusively is expressed in mitochondria appeared strongly
protective against glucose-induced ROS, AGEs and sorbi-
tol formation in endothelial cells [22], corroborating the
prominent role of mitochondria in ROS-induced renal cell
apoptosis.
Transgenic mice overexpressing thioredoxin-1 were
protected against diabetic nephropathy as shown by
reduced albuminuria and tubular apoptosis [67]. Further-
more, markers of systemic and renal oxidative stress were
attenuated in this model, again indicating a signiﬁcant role
for oxidative stress in the development of diabetic
nephropathy. Transgenic mice overexpressing peroxire-
doxin-3, a mitochondria-speciﬁc thioredoxin peroxidase,
caused a reduction of mitochondrial-produced H2O2 and an
increased resistance to stress-induced ﬁbroblast cell death
and apoptosis [69], whereas, surprisingly, glutathione per-
oxidase-1-deﬁcient animals showed similar levels of dia-
betes-induced kidney injury as wild type controls [70].
Inhibition of mitochondrial NADPH-dependent isocitrate
dehydrogenase activity led to an increase of apoptosis
mediated by active caspase-3, PARP and a decreased Bcl-2
expression, whereas overexpression of the enzyme resulted
in decreased apoptosis of HEK293 cells associated with a
decreased expression in PARP and Bax [71]. Also in other
studies it was shown that reduction of oxidative stress by
anti-oxidant enzyme activity led to improved renal function
after hyperglycemic injury because of a reduction in
tubular cell apoptosis [72, 73].
Activated PC mediates protection against mitochondrial
apoptosis in the glomerulus, while high glucose levels
abrogate activation of PC and its down-stream protective
pathways. Interestingly, it has recently been found that
increasing activated PC during hyperglycemia avoids oxi-
dative stress and restores activated PC-mediated cytopro-
tection, and prevents mitochondria-dependent apoptosis of
endothelial cells and podocytes, and diabetic nephropathy
in T1DM [19, 56].
In summary, anti-oxidants and cytoprotective proteins
can counteract ROS-induced apoptosis of renal cells and
the development of diabetic nephropathy (see also Table 1,
Fig. 1).
Concluding remarks
In the diabetic kidney ROS are produced via different
pathways. When cytoprotective and anti-oxidant capacity
is insufﬁcient, ROS will induce apoptosis, which may
ﬁnally result in diabetic nephropathy. Therapeutic options
may include restoration of the redox balance by anti-oxi-
dant compounds such as vitamin C and E. Unfortunately,
routine anti-oxidants have demonstrated minimal renopro-
tection in humans with diabetic nephropathy, despite many
positive observations in animal models [4]. However, for
the treatment or prevention of diabetic nephropathy, the
induction of cytoprotective proteins with anti-oxidant
activities, such as PC, catalase, SOD and HO-1, constitute
a valid alternative strategy. In fact, manipulating cytopro-
tective proteins and their effector molecules seem to reduce
apoptosis in the diabetic kidney, and may therefore be
beneﬁcial, as demonstrated in animal models for diabetic
nephropathy. These observations warrant further transla-
tional approaches addressing cytoprotective proteins in
humans with diabetic nephropathy.
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